ArticleFree radical biology & medicine2016
Nitro-oleic acid modulates classical and regulatory activation of macrophages and their involvement in pro-fibrotic responses.
Article in Free radical biology & medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 50 citations in OpenAlex.
- Gassericins from Lactobacillus Paragasseri K7: Preparative Isolation and Discovery of Dose-Dependent Anti-Inflammatory Effects.Probiotics and antimicrobial proteins · 2026Article
- Nitro-oleic acid activation of endothelial PPARγ signaling pathway alleviates neurovascular injury and improves functional outcomes in ischemic stroke.Brain pathology (Zurich, Switzerland) · 2026Article
- Ultrasound targeted fatty acid nitroalkene-containing lipid nanoparticles attenuate inflammation and reverse myocardial fibrosis.Theranostics · 2026Article
- Neuroprotective actions of a fatty acid nitroalkene in Parkinson's disease.NPJ Parkinson's disease · 2023Article
- Meta-omics profiling of the gut-lung axis illuminates metabolic networks and host-microbial interactions associated with elevated lung elastance in a murine model of obese allergic asthma.Frontiers in microbiomes · 2023Article
- Fatty acid nitroalkene reversal of established lung fibrosis.Redox biology · 2022Article
- Lipid nitroalkene nanoparticles for the focal treatment of ischemia reperfusion.Nanotheranostics · 2022Article
- Nitro Fatty Acids (NOMolecules (Basel, Switzerland) · 2021Review
- M2c Macrophages enhance phalange regeneration of amputated mice digits in an organ co-culture system.Iranian journal of basic medical sciences · 2021Article
- Suppression of Vascular Macrophage Activation by Nitro-Oleic Acid and its Implication for Abdominal Aortic Aneurysm Therapy.Cardiovascular drugs and therapy · 2021Article
- Chemoproteomic profiling reveals cellular targets of nitro-fatty acids.Redox biology · 2021Article
- Nitroalkene fatty acids modulate bile acid metabolism and lung function in obese asthma.Scientific reports · 2021Article
- Fatty acid nitroalkenes inhibit the inflammatory response to bleomycin-mediated lung injury.Toxicology and applied pharmacology · 2020Article
- The effect ofVeterinary world · 2020Article
- Complex interrelationships between nitro-alkene-dependent inhibition of soluble epoxide hydrolase, inflammation and tumor growth.Redox biology · 2020Article
- Nitro-Fatty Acid Logistics: Formation, Biodistribution, Signaling, and Pharmacology.Trends in endocrinology and metabolism: TEM · 2019Review
- Nitrated fatty acids: from diet to disease.Current opinion in physiology · 2019Article
- Discovery of bioactive nitrated lipids and nitro-lipid-protein adducts using mass spectrometry-based approaches.Redox biology · 2019Review
- Post-Translational Modification of Proteins Mediated by Nitro-Fatty Acids in Plants: Nitroalkylation.Plants (Basel, Switzerland) · 2019Review
- Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice.EBioMedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
Inflammation is an immune response triggered by microbial invasion and/or tissue injury. While acute inflammation is directed toward invading pathogens and injured cells, thus enabling tissue regeneration, chronic inflammation can lead to severe pathologies and tissue dysfunction. These processes are linked with macrophage polarization into specific inflammatory "M1-like" or regulatory "M2-like" subsets. Nitro-fatty acids (NO2-FAs), produced endogenously as byproducts of metabolism and oxidative inflammatory conditions, may be useful for treating diseases associated with dysregulated immune homeostasis. The goal of this study was to characterize the role of nitro-oleic acid (OA-NO2) in regulating the functional specialization of macrophages induced by bacterial lipopolysaccharide or interleukin-4, and to reveal specific signaling mechanisms which can account for OA-NO2-dependent modulation of inflammation and fibrotic responses. Our results show that OA-NO2 inhibits lipopolysaccharide-stimulated production of both pro-inflammatory and immunoregulatory cytokines (including transforming growth factor-β) and inhibits nitric oxide and superoxide anion production. OA-NO2 also decreases interleukin-4-induced macrophage responses by inhibiting arginase-I expression and transforming growth factor-β production. These effects are mediated via downregulation of signal transducers and activators of transcription, mitogen-activated protein kinase and nuclear factor-кB signaling responses. Finally, OA-NO2 inhibits fibrotic processes in an in vivo model of angiotensin II-induced myocardial fibrosis by attenuating expression of α-smooth muscle actin, systemic transforming growth factor-β levels and infiltration of both "M1-" and "M2-like" macrophage subsets into afflicted tissue. Overall, the electrophilic fatty acid derivative OA-NO2 modulates a broad range of "M1-" and "M2-like" macrophage functions and represents a potential therapeutic approach to target diseases associated with dysregulated macrophage subsets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.